Sort   by:  
 Page size 
ProteomicsDT2216 is a specific BCL-XL PROTAC
To validate the specificity of DT2216, we used the stable isotope labeling with amino acids in cell culture (SILAC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics to analyze the changes in proteins in WI-38 normal human diploid fibroblasts after DT2216 and DT2216NC tr...
ORGANISM(S): Homo sapiens (Human) 
2019-10-08 | PXD010878 | Pride
Dt2216 bcl-xl protac silac lc-ms/ms 
ProteomicsIdentification of ubiquitination site in BCL-XL after PROTAC DT2216 treatment
The availability of a suitable lysine for PROTAC-mediated ubiquitination can also determine the degradative ability of a protein target and the selectivity of a PROTAC. PROTAC DT2216 selectively triggers ubiquitination and degradation of BCL-XL. In this study, we identify K87 is the key ubiquitinate...
ORGANISM(S): Homo sapiens (Human) 
2019-10-08 | PXD015454 | Pride
Bcl-xl Ubiquitination site K87 Protac Dt2216 
GenomicsBCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
PRJNA917319 | ENA
TranscriptomicsBCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
We demonstrated that secondary Plasma Cell Leukemia, addicted to BCLXL, a small but a very challenging group of patients, could benefit from DT2216, underpinning its clinical evaluation.
ORGANISM(S): Homo sapiens 
2024-01-30 | GSE222016 | GEO
UnknownBCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
Not available
S-EPMC10393035 | biostudies-literature
UnknownDT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
Not available
S-EPMC7364785 | biostudies-literature
UnknownResistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
Not available
S-EPMC10405225 | biostudies-literature
UnknownEfficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
Not available
S-EPMC12333229 | biostudies-literature
UnknownOvercoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Not available
S-EPMC8742767 | biostudies-literature
UnknownBCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
Not available
S-EPMC8905794 | biostudies-literature
Sort   by:  
 Page size